The gut-brain axis represents a bidirectional communication network linking the gastrointestinal tract with the central nervous system through neural, hormonal, immunological, and metabolic pathways. This complex interface has emerged as a critical regulator of brain health and a potential contributor to neurodegenerative processes in [tau](/proteins/tau-protein)opathies including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer's disease.
The [gut-brain axis](/mechanisms/gut-brain-axis) comprises multiple interconnected pathways that enable continuous crosstalk between the [intestinal ecosystem](/cell-types/enteric-neurons) and the [brain](/brain-regions)[@cryan2024]. The [gastrointestinal tract](/diseases/gastrointestinal-disorders) houses the [enteric nervous system](/cell-types/enteric-neurons) (ENS), often called the "second brain," which contains over 500 million [neurons](/cell-types/neurons) and communicates with the [central nervous system](/brain-regions) through the [vagus nerve](/brain-regions/vagus-nerve)[@furness2012]. This bidirectional highway transmits signals in both directions—from gut to [brain](/brain-regions) and from [brain](/brain-regions) to gut—creating a continuous feedback loop that influences [neurodevelopment](/mechanisms/neurodevelopment), [behavior](/diseases/behavioral-disorders), and [neurodegeneration](/mechanisms/neurodegeneration).
The gut-brain axis represents a bidirectional communication network linking the gastrointestinal tract with the central nervous system through neural, hormonal, immunological, and metabolic pathways. This complex interface has emerged as a critical regulator of brain health and a potential contributor to neurodegenerative processes in [tau](/proteins/tau-protein)opathies including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer's disease.
The [gut-brain axis](/mechanisms/gut-brain-axis) comprises multiple interconnected pathways that enable continuous crosstalk between the [intestinal ecosystem](/cell-types/enteric-neurons) and the [brain](/brain-regions)[@cryan2024]. The [gastrointestinal tract](/diseases/gastrointestinal-disorders) houses the [enteric nervous system](/cell-types/enteric-neurons) (ENS), often called the "second brain," which contains over 500 million [neurons](/cell-types/neurons) and communicates with the [central nervous system](/brain-regions) through the [vagus nerve](/brain-regions/vagus-nerve)[@furness2012]. This bidirectional highway transmits signals in both directions—from gut to [brain](/brain-regions) and from [brain](/brain-regions) to gut—creating a continuous feedback loop that influences [neurodevelopment](/mechanisms/neurodevelopment), [behavior](/diseases/behavioral-disorders), and [neurodegeneration](/mechanisms/neurodegeneration).
The [intestinal microbiome](/mechanisms/microbiome-brain-axis), comprising trillions of bacteria, fungi, viruses, and archaea, plays a central role in [gut-brain axis](/mechanisms/gut-brain-axis) signaling[@sender2016]. These microorganisms produce [metabolites](/mechanisms/metabolic-dysfunction), [neurotransmitters](/mechanisms/neurotransmitter-systems), and [inflammatory mediators](/mechanisms/neuroinflammation) that can cross the intestinal barrier, enter [systemic circulation](/diseases/systemic-inflammation), and directly influence [brain function](/brain-regions). In [neurodegenerative diseases](/diseases/alzheimers-disease), the composition and function of the [gut microbiome](/mechanisms/microbiome-brain-axis) undergo characteristic changes that may contribute to [disease pathogenesis](/mechanisms/neurodegeneration) or serve as [biomarkers](/biomarkers/gut-microbiome-biomarkers) of [disease progression](/diseases/progressive-supranuclear-palsy).
Seminal research by [Vogt and colleagues](/researchers/nathaniel-vogt) (2018) demonstrated that patients with [PSP](/diseases/progressive-supranuclear-palsy) exhibit profound alterations in [gut microbiome](/mechanisms/microbiome-brain-axis) composition compared to healthy controls[@vogt2018]. Their study of 99 PSP patients and 90 age-matched controls revealed significant reductions in bacterial diversity and distinct shifts in microbial taxa. Notably, PSP patients showed decreased abundance of Prevotellaceae, Ruminococcaceae, and other [butyrate-producing bacteria](/mechanisms/short-chain-fatty-acids), alongside increases in Escherichia and other opportunistic pathogens.
These findings have been extended by subsequent studies demonstrating similar [microbiome disruptions](/mechanisms/microbiome-brain-axis) in [corticobasal syndrome](/diseases/corticobasal-degeneration)[@keshavarzian2023]. The pattern of dysbiosis in [tau](/proteins/tau-protein)opathies](/mechanisms/[tau](/proteins/tau-protein)opathies) differs from that observed in [Alzheimer's disease](/diseases/alzheimers-disease), suggesting disease-specific microbiome signatures that may reflect distinct [pathophysiological mechanisms](/mechanisms/neurodegeneration). The reduction in [butyrate-producing bacteria](/mechanisms/short-chain-fatty-acids) is particularly concerning, as butyrate serves as the primary energy source for colonocytes and exerts potent [anti-inflammatory effects](/mechanisms/neuroinflammation).
The [Alzheimer's disease](/diseases/alzheimers-disease) literature provides extensive evidence for [gut microbiome](/mechanisms/microbiome-brain-axis) alterations that may inform our understanding of [tau](/proteins/tau-protein)opathies](/mechanisms/[tau](/proteins/tau-protein)opathies). A meta-analysis of 17 studies involving over 2,000 AD patients identified consistent reductions in microbial diversity and decreases in beneficial genera including [Bifidobacterium](/bacteria/bifidobacterium) and [Lactobacillus](/bacteria/lactobacillus)[@jia2024]. Conversely, pro-inflammatory taxa such as [Escherichia](/bacteria/escherichia) and [Shigella](/bacteria/shigella) were increased, correlating with markers of [systemic inflammation](/mechanisms/neuroinflammation).
The "gut leakage" hypothesis proposes that [microbiome dysbiosis](/mechanisms/microbiome-brain-axis) compromises intestinal barrier integrity, allowing bacterial products to translocate into [systemic circulation](/diseases/endotoxemia)[@powell2017]. This [endotoxemia](/diseases/endotoxemia) activates [peripheral immune cells](/cell-types/immune-cells) and promotes [neuroinflammation](/mechanisms/neuroinflammation) through multiple mechanisms, including [cytokine-mediated activation](/mechanisms/cytokine-signaling) of brain [microglia](/cell-types/microglia) and direct transport of [microbial metabolites](/mechanisms/short-chain-fatty-acids) across the [blood-brain barrier](/mechanisms/blood-brain-barrier-dysfunction).
[Short-chain fatty acids](/mechanisms/short-chain-fatty-acids) (SCFAs), particularly [butyrate](/mechanisms/short-chain-fatty-acids), propionate, and acetate, represent the primary metabolites produced by [bacterial fermentation](/mechanisms/microbiome-brain-axis) of dietary fiber in the colon[@dalile2019]. These molecules serve as crucial signaling molecules in the [gut-brain axis](/mechanisms/gut-brain-axis), influencing [brain function](/brain-regions) through multiple pathways.
[Butyrate](/mechanisms/short-chain-fatty-acids), produced predominantly by members of the [Ruminococcaceae](/bacteria/ruminococcaceae) and [Lachnospiraceae](/bacteria/lachnospiraceae) families, exerts potent [anti-inflammatory effects](/mechanisms/neuroinflammation) through inhibition of [histone deacetylases](/proteins/hdac) (HDACs) and activation of [G-protein-coupled receptors](/proteins/gpcr) (GPR41, GPR43, GPR109A)[@stilling2023]. In the [brain](/brain-regions), butyrate can modulate [microglial activation](/cell-types/microglia), reduce [pro-inflammatory cytokine](/mechanisms/cytokine-signaling) production, and enhance [neurotrophic factor](/proteins/bdnf) expression.
Animal studies demonstrate that butyrate administration ameliorates cognitive deficits in mouse models of AD and reduces [tau](/proteins/tau-protein) pathology phosphorylation[@liu2021]. These effects appear mediated through multiple mechanisms, including HDAC inhibition leading to enhanced expression of neurotrophic genes, reduced neuroinflammation, and improved blood-brain barrier integrity. The depletion of butyrate-producing bacteria observed in PSP and CBS patients may therefore contribute to disease progression through loss of these protective effects.
Propionate, primarily produced by Bacteroidetes species, enters systemic circulation and can cross the blood-brain barrier to influence central nervous system function[@silva2023]. In the brain, propionate modulates microglial morphology and function, promotes expression of anti-inflammatory cytokines, and may protect against excitotoxicity. Acetate, the most abundant SCFA, serves as a substrate for lipogenesis in the brain and influences food intake through hypothalamic signaling.
Lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, represents a potent trigger of systemic inflammation when translocated across the compromised intestinal barrier[@ghosh2024]. Elevated serum LPS levels have been documented in both AD and PSP patients, correlating with disease severity and markers of neuroinflammation.
The "LPS hypothesis" proposes that chronic low-grade endotoxemia from gut microbiome dysbiosis contributes to neurodegenerative processes through sustained activation of innate immune responses[@pistollato2019]. LPS binds to Toll-like receptor 4 (TLR4) on microglia and peripheral immune cells, triggering the NF-κB signaling cascade and production of pro-inflammatory cytokines including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α).
These cytokines can enter the brain through circumventricular organs with permeable blood-brain barriers, or be actively transported across the barrier by saturable transport systems. Once in the CNS, they activate microglia, promote neuroinflammation, and can directly influence [tau](/proteins/tau-protein) phosphorylation through activation of [tau](/proteins/tau-protein) kinases including glycogen synthase kinase-3β (GSK3β) and cyclin-dependent kinase 5 (CDK5)[@li2023].
Experimental evidence links LPS exposure to accelerated [tau](/proteins/tau-protein) pathology in animal models. Injection of LPS into the brain parenchyma or systemic administration promotes [tau](/proteins/tau-protein) hyperphosphorylation and accumulation in mouse models of [tau](/proteins/tau-protein)opathy[@chen2022]. The mechanism involves microglial activation, cytokine production, and direct effects on neuronal signaling pathways that regulate [tau](/proteins/tau-protein) kinases and phosphatases.
The essential amino acid tryptophan, obtained from dietary protein, serves as a precursor for multiple bioactive molecules including serotonin, melatonin, and kynurenine pathway metabolites[@platten2019]. The gut microbiome influences tryptophan metabolism, shifting the balance between neuroprotective serotonin production and potentially neurotoxic kynurenine derivatives.
The kynurenine pathway accounts for approximately 95% of tryptophan metabolism and produces several neuroactive metabolites including kynurenic acid (KYNA) and quinolinic acid (QUIN)[@schwarcz2023]. KYNA acts as an antagonist of NMDA and α7 nicotinic receptors, potentially providing neuroprotection at low concentrations. In contrast, QUIN serves as an NMDA receptor agonist that promotes excitotoxicity, oxidative stress, and microglial activation.
Elevated QUIN levels have been documented in cerebrospinal fluid and brain tissue from AD and PSP patients[@chen2024]. The increased QUIN/KYNA ratio observed in neurodegenerative diseases may contribute to excitotoxic neuronal loss and disease progression. Gut microbiome dysbiosis can shift tryptophan metabolism toward kynurenine production through activation of indoleamine 2,3-dioxygenase (IDO) by inflammatory cytokines.
The vagus nerve, the longest cranial nerve, provides the primary neural conduit for gut-brain communication[@bonaz2024]. Approximately 80% of vagal afferent fibers transmit sensory information from visceral organs to the brain, while efferent fibers regulate gastrointestinal motility, secretion, and immune function.
Vagal afferents express receptors for SCFAs, gut hormones, and bacterial metabolites, allowing direct detection of gut luminal contents and transmission of this information to brainstem nuclei including the nucleus tractus solitarius (NTS)[@breit2018]. From the NTS, signals propagate to higher brain regions including the hypothalamus, amygdala, and prefrontal cortex, influencing autonomic function, mood, and cognition.
In [Parkinson's disease](/diseases/parkinsons-disease)'s disease, alpha-synuclein pathology has been detected in the enteric nervous system years before motor symptoms appear, suggesting that pathological proteins may propagate from gut to brain via the vagus nerve[@braak2023]. While less studied in [tau](/proteins/tau-protein)opathies, similar prion-like propagation mechanisms may operate, with [tau](/proteins/tau-protein) aggregates seeding in the gut and trafficking retrogradely along vagal fibers to the dorsal motor nucleus of the vagus and ultimately to the basal ganglia and cortical regions.
Beyond microbiome changes, CBS and PSP patients commonly exhibit gastrointestinal symptoms that may reflect pathology in the enteric nervous system or vagal signaling pathways[@mertsalmi2023]. These include constipation, gastroparesis, and altered gastric acid secretion, with constipation being particularly prevalent and often predating motor symptoms by years.
The autonomic nervous system, heavily innervated by vagal fibers, is frequently affected in [tau](/proteins/tau-protein)opathies[@baschieri2023]. Cardiovascular autonomic testing reveals reduced heart rate variability and impaired baroreflex function in PSP patients, indicating dysfunction in both sympathetic and parasympathetic pathways. These abnormalities may reflect brainstem involvement in [tau](/proteins/tau-protein)opathies and contribute to GI dysmotility through disordered vagal efferent signaling.
Probiotic supplementation with beneficial bacterial strains represents a therapeutic strategy to restore microbiome balance and reduce neuroinflammation[@den2023]. Clinical trials in AD patients have demonstrated that probiotic formulations containing Bifidobacterium and Lactobacillus species can improve cognitive function and reduce inflammatory markers. Similar approaches may benefit CBS and PSP patients, though dedicated trials are lacking.
Prebiotics, non-digestible fibers that selectively promote growth of beneficial bacteria, offer an alternative approach to enhance SCFA production[@vamanu2024]. Dietary fibers including inulin, fructooligosaccharides (FOS), and galacto-oligosaccharides (GOS) have been shown to increase butyrate-producing bacteria and reduce systemic inflammation in human studies.
Fecal microbiome transplantation (FMT), the transfer of stool from healthy donors to recipients, represents the most direct approach to microbiome restoration[@vendrik2024]. Originally developed for Clostridioides difficile infection, FMT is being investigated for neurodegenerative diseases. A pilot study in [Parkinson's disease](/diseases/parkinsons-disease)'s disease demonstrated improvements in motor symptoms following FMT, though controlled trials are needed.
The Mediterranean diet, rich in vegetables, fruits, legumes, olive oil, and fish, has been associated with reduced AD risk and slower cognitive decline[@dominguez2024]. These benefits may be mediated through gut microbiome modulation, as Mediterranean diet adherence correlates with increased beneficial bacterial taxa and higher SCFA production. Similar dietary approaches may benefit [tau](/proteins/tau-protein)opathy patients, though specific studies are lacking.
Despite growing evidence for gut-brain axis involvement in [tau](/proteins/tau-protein)opathies, significant knowledge gaps remain. Longitudinal studies tracking microbiome changes from pre-symptomatic stages through disease progression are needed to determine whether dysbiosis represents a cause or consequence of neurodegeneration. Interventional studies examining the therapeutic potential of microbiome modulation in CBS and PSP are urgently required.
The development of gut-targeted biomarkers, including microbial metabolites and intestinal permeability markers, may enable early detection and monitoring of treatment response. Additionally, understanding host-microbiome interactions at the molecular level will facilitate development of targeted interventions that restore beneficial functions without requiring live microorganism administration.
The blood-brain barrier (BBB), composed of tightly joined endothelial cells, pericytes, and astrocyte end-feet, serves as a critical interface regulating passage of molecules between systemic circulation and the brain parenchyma[@ballabh2024]. Gut microbiome-derived metabolites can influence BBB integrity through multiple mechanisms, potentially facilitating entry of pro-inflammatory molecules into the CNS.
SCFAs, particularly butyrate, play a dual role in BBB regulation. At physiological concentrations, butyrate enhances BBB integrity by upregulating tight junction proteins including claudin-5 and occludin[@braniste2014]. However, at high concentrations or in the context of systemic inflammation, butyrate can increase BBB permeability through effects on endothelial cell metabolism and transport systems.
Elevated circulating LPS promotes BBB dysfunction through activation of endothelial TLR4 and subsequent production of matrix metalloproteinases (MMPs) that degrade tight junction proteins[@banks2023]. This compromised barrier allows peripheral cytokines, immune cells, and bacterial products to enter the brain parenchyma, propagating neuroinflammation and potentially accelerating [tau](/proteins/tau-protein) pathology spread.
Certain microbial metabolites can cross the BBB through saturable transport systems. The kynurenine pathway metabolite quinolinic acid enters the brain via large neutral amino acid transporters, with brain uptake increasing in conditions of systemic inflammation[@kita2024]. Once in the CNS, QUIN can directly activate microglia, promote oxidative stress, and exacerbate [tau](/proteins/tau-protein) phosphorylation through NMDA receptor-mediated mechanisms.
The inflammatory cytokine network represents a critical bridge between gut-derived signals and brain pathology. Pro-inflammatory cytokines produced in response to microbiome dysbiosis can influence [tau](/proteins/tau-protein) metabolism through multiple signaling pathways[@kinney2024].
Interleukin-1β (IL-1β), a key cytokine elevated in both AD and PSP patients, promotes [tau](/proteins/tau-protein) hyperphosphorylation through activation of p38 MAPK and JNK signaling pathways[@li2023a]. In microglia, IL-1β production is triggered by LPS recognition through TLR4, creating a pathway from gut-derived endotoxemia to neuronal [tau](/proteins/tau-protein) pathology. Animal studies demonstrate that chronic IL-1β overexpression in the brain leads to [tau](/proteins/tau-protein) hyperphosphorylation and cognitive deficits, supporting its role as a mechanistic link between peripheral inflammation and central [tau](/proteins/tau-protein)opathy.
Tumor necrosis factor-α (TNF-α), another pro-inflammatory cytokine elevated in [tau](/proteins/tau-protein)opathies, contributes to neurodegeneration through both direct neuronal effects and amplification of neuroinflammation[@cheng2024]. TNF-α can activate [tau](/proteins/tau-protein) kinase pathways including GSK3β and CDK5, while also promoting synaptic dysfunction and neuronal apoptosis. The finding that anti-TNF therapies show promise in neurodegenerative diseases highlights the potential for cytokine-targeted interventions.
Germ-free mice, lacking any gut microbiota, have provided crucial insights into the role of the microbiome in brain function and disease[@bostrom2024]. Studies in AD mouse models demonstrate that germ-free status reduces cerebral amyloid plaque formation and improves cognitive performance, suggesting that the microbiome promotes amyloid pathology. Conversely, germ-free PS19 [tau](/proteins/tau-protein)opathy mice show attenuated [tau](/proteins/tau-protein) pathology and neuroinflammation, indicating microbiome-dependent effects on [tau](/proteins/tau-protein) metabolism.
Fecal microbiota transplantation from AD or PSP patients into germ-free mice transfers disease-relevant phenotypes including altered microbiome composition, increased systemic inflammation, and in some studies, accelerated brain pathology[@peng2024]. These experiments support a causal role for gut microbiome alterations in neurodegenerative processes.
Administration of broad-spectrum antibiotics depletes the gut microbiome and has been used to probe microbiome-dependent effects on neurodegeneration[@dodiya2023]. In AD mouse models, antibiotic treatment reduces amyloid plaque burden and microglial activation, effects reversible upon fecal transplantation. However, long-term antibiotic use in humans is associated with increased dementia risk, suggesting that microbiome depletion may have complex and potentially adverse effects on brain health.
Constipation represents one of the most common and earliest gastrointestinal symptoms in CBS and PSP patients[@jost2024]. Colonic transit studies reveal significantly delayed transit times in PSP patients compared to age-matched controls, even in early disease stages. This dysmotility may reflect degeneration of the enteric nervous system, vagal dysfunction, or medication effects.
The prevalence of severe constipation (fewer than three bowel movements per week) exceeds 70% in PSP patients, compared to approximately 30% in age-matched controls[@knudsen2023]. This symptom often precedes motor symptoms by years, raising the possibility that gut dysfunction may serve as an early biomarker or even contribute to disease pathogenesis through chronic endotoxemia.
Small intestinal bacterial overgrowth (SIBO), characterized by excessive bacterial colonization of the proximal small intestine, has been documented in both [Parkinson's disease](/diseases/parkinsons-disease)'s disease and PSP patients[@tan2024]. SIBO can cause malabsorption, bloating, and increased intestinal permeability, potentially amplifying systemic inflammation. Treatment of SIBO with antibiotics has been associated with improved motor symptoms in [Parkinson's disease](/diseases/parkinsons-disease)'s disease, though similar studies in [tau](/proteins/tau-protein)opathies are lacking.
Multiple therapeutic strategies targeting the gut-brain axis are under investigation for neurodegenerative diseases. These approaches share the common goal of restoring beneficial microbiome functions while reducing pro-inflammatory signals[@cryan2024a].
Synbiotic products combining probiotics with prebiotic substrates offer a dual approach to microbiome modulation. By providing both beneficial bacteria and their preferred energy sources, synbiotics may more effectively establish and maintain favorable microbiome composition. Early clinical trials in AD patients demonstrate cognitive benefits with synbiotic formulations, though large-scale controlled studies are needed[@asaoka2023].
Reducing gut-derived inflammation represents another therapeutic strategy. Dietary interventions including omega-3 fatty acid supplementation can reduce systemic inflammation and may improve microbiome composition[@la2024]. Similarly,-targeted approaches using monoclonal antibodies against IL-1β or TNF-α are under investigation for neurodegenerative diseases.
Vagus nerve stimulation (VNS), an approach already FDA-approved for epilepsy and depression, may modulate gut-brain axis signaling. Experimental studies demonstrate that VNS reduces peripheral inflammation through the cholinergic anti-inflammatory pathway and improves cognitive function in AD models[@howland2024]. Clinical trials of VNS in AD and PSP patients are ongoing.
Fecal microbiome composition analysis offers a non-invasive approach to identify disease-specific signatures and monitor treatment response. In PSP, reduced microbial diversity and altered Firmicutes to Bacteroidetes ratios show promise as diagnostic biomarkers[@houser2024]. Serum markers of intestinal permeability, including zonulin and FABP2, may also serve as indicators of gut barrier dysfunction.
Metabolomic profiling of serum and cerebrospinal fluid can detect alterations in microbial metabolites that reflect gut microbiome function. Elevated trimethylamine N-oxide (TMAO), a gut microbial metabolite linked to cardiovascular disease and cognitive decline, has been documented in AD and PSP patients[@vogt2024]. Monitoring TMAO and other microbial metabolites may enable tracking of treatment response and disease progression.
The gut-brain axis represents a critical yet underappreciated pathway in [tau](/proteins/tau-protein)opathies including CBS and PSP. Evidence of microbiome dysbiosis, impaired barrier integrity, altered SCFA production, and kynurenine pathway activation points to the intestine as both a potential trigger and therapeutic target for neurodegenerative processes. Restoration of gut microbiome homeostasis through probiotics, prebiotics, dietary modification, or FMT offers a novel approach to disease modification that warrants rigorous clinical investigation.